Aligos Therapeutics is on a mission to become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.

Scientific Overview: Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.